Securities code: 002294 securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022-004 Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Announcement on the provision for asset impairment
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without falsehood
False records, misleading statements or material omissions.
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (hereinafter referred to as “the company”) convened the 24th Meeting of the 5th board of directors on December 30, 2021. The proposal on the provision for asset impairment was deliberated and adopted with 9 consent, 0 opposition and 0 abstention. The details are as follows:
1、 Overview of provision for asset impairment this time
(i) Reasons for withdrawing provision for asset impairment
In order to more truly and objectively reflect the company’s financial status, asset value and operating status, according to the accounting standards for business enterprises and the relevant provisions of the company’s accounting policies, the company evaluates the recoverable value of the asset group of Suzhou Huanchen Medical Technology Co., Ltd. (hereinafter referred to as “Suzhou Huanchen”) as of October 31, 2021, The impairment test is conducted on the relevant assets with impairment signs on the balance sheet date. If the impairment test results show that there are signs of impairment, the recoverable amount is estimated, and the impairment provision is withdrawn according to the amount that the recoverable amount is lower than the book value.
（2） The asset scope, total amount and reporting period to be included in the provision for asset impairment this time
Since January 2021, the national centralized procurement of coronary stents has been officially implemented and strictly implemented in all localities. Hospitals at all levels in some provinces and cities (such as Hebei, Tianjin, etc.) have basically purchased all the winning stents, and the market space outside the centralized procurement has shrunk significantly; At the same time, the repeated and sporadic outbreaks of local epidemics make the number of elective operations lower than expected, resulting in differences in the actual sales quantity and sales price of alpha stent in 2021 compared with last year’s expectations. It is expected that Huanchen’s profitability will still be adversely affected in the future, and the sustainability of the adverse impact is uncertain.
Therefore, the company conducted an impairment test on the recoverable value of the asset group formed by the merger and acquisition of Huanchen. The impairment test results show that there are signs of impairment of intangible assets in relevant asset groups. Based on the principle of prudence, the impairment provision for these assets is withdrawn. In the fourth quarter of 2021, the company made an impairment provision of 120.8573 million yuan for the intangible assets of Huanchen asset group. After the withdrawal, the net book value of intangible assets in Huanchen asset group is 0 yuan.
The reporting period to be included in the provision for asset impairment this time is the fourth quarter of 2021.
（3） Specific description of individual provision for asset impairment
The company’s single provision for impairment of intangible assets is 120.8573 million yuan, accounting for more than 30% of the company’s audited net profit in the latest fiscal year and the absolute amount is more than 10 million yuan. According to relevant regulations, the details are as follows:
Asset Name: intangible assets
Book value (10000 yuan) 1208573
Recoverable amount of assets (yuan) 0
When the relevant asset group complies with the future business plan, the calculation process of the recoverable amount of the recoverable assets of the relevant assets is evaluated
Amount received.
According to the relevant provisions of the accounting standards for business enterprises, the recoverable amount of intangible assets is lower than the book value, which is the basis for the current provision for asset impairment
The impairment provision shall be withdrawn according to the difference and included in the asset impairment loss.
Accrued amount (10000 yuan) 1208573
The company judges that there are signs of impairment in the asset group, and after evaluation, the reason for the withdrawal of the asset group in the current period
The recoverable amount at the end of is less than the book value, so the impairment provision is withdrawn according to the difference.
（4） Approval procedure
The proposal on withdrawing provision for asset impairment has been deliberated and adopted at the 24th Meeting of the 5th board of directors and the 18th meeting of the 5th board of supervisors, and independent directors have expressed independent opinions on it.
In accordance with the Listing Rules of Shenzhen Stock Exchange, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and the articles of association, the provision for asset impairment is within the decision-making authority of the board of directors of the company and does not need to be submitted to the general meeting of shareholders for deliberation and approval.
2、 Recognition standard and withdrawal method of the provision for impairment of intangible assets
If there are signs of impairment of long-term assets on the balance sheet date, impairment test shall be conducted. If the impairment test results show that the recoverable amount of the asset is lower than its book value, the impairment provision shall be withdrawn according to the difference and included in the impairment loss.
According to the appraisal report on the recoverable value of the asset group of Suzhou Huanchen Medical Technology Co., Ltd. involved in the preparation of the financial report by Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Biomedical Engineering Co., Ltd. (Lianxin (Zheng) pingbao Zi [2021] No. z0952) issued by Guangdong Lianxin asset appraisal Land Real Estate Appraisal Co., Ltd., as of the benchmark date of October 31, 2021, The recoverable amount is 4.7764 million yuan.
The company conducted impairment test according to the evaluation results. According to the impairment test results, the impairment provision for intangible assets at the consolidation level in the fourth quarter of 2021 was 120.8573 million yuan, mainly due to the test of the asset group formed by the company’s merger and acquisition of Huanchen according to Huanchen’s actual operation in 2021 and the expectation of future market conditions. 3、 The impact of the current provision for asset impairment on the company
The total provision for asset impairment of the company is 120.8573 million yuan. After considering the impact of deferred income tax expenses, the net profit attributable to the owner of the parent company in the consolidated statements of the corresponding company in 2021 decreases by 102.7287 million yuan and the owner’s equity attributable to the parent company decreases by 102.7287 million yuan.
The company’s provision for asset impairment has not been audited by an accounting firm, and the final data shall be subject to the financial data audited by an accounting firm.
4、 Notes of the board of directors, the board of supervisors and independent directors on this matter
(i) Opinions of the board of directors
The board of Directors believes that the provision for asset impairment this time complies with the accounting standards for business enterprises, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and the relevant accounting policies of the company, and the basis for the provision for asset impairment is sufficient and reasonable. The accrued financial statements can more objectively and fairly reflect the company’s financial status and operating results, which is reasonable. The board of directors agrees that the company shall withdraw the provision for asset impairment in accordance with the relevant provisions of the accounting standards for business enterprises.
（2） Opinions of the board of supervisors
The board of supervisors believes that the provision for asset impairment is in line with the principle of prudence and relevant provisions of the accounting standards for business enterprises, and the basis for the provision is sufficient and in line with the actual situation of the company’s assets; The decision-making procedure of this matter complies with the provisions of relevant laws and regulations and the articles of association, and there is no situation that damages the interests of the company and minority shareholders. The board of supervisors agreed to withdraw the provision for asset impairment this time.
（3） Opinions of independent directors
The company’s provision for asset impairment this time follows the principle of prudence and complies with the relevant provisions of the accounting standards for business enterprises and the actual situation of the company’s assets. The accrued financial statements can more objectively and fairly reflect the company’s asset status and operating results, and there is no damage to the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. Necessary procedures have been implemented for this decision, and relevant approval and decision-making procedures are legal and compliant. We agree that the company will withdraw the provision for asset impairment this time.
5、 Documents for future reference
1. Resolutions of the 24th Meeting of the 5th board of directors;
2. Independent opinions expressed by independent directors on relevant matters of the company;
3. Resolutions of the 18th meeting of the 5th board of supervisors;
4. Other documents required by CSRC and Shenzhen Stock Exchange.
It is hereby announced
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) board of directors
January 4, 2002
